Michael R. Kilbourn, Ph.D.
Dr. Kilbourn has more than 30 years of experience in radiopharmaceutical chemistry, including radionuclide production, radiochemistry, radiopharmaceutical development and preclinical evaluation, and routine delivery of radiotracers for clinical research and patient care. He has experience in cyclotron target design, development of new methods and reagents for radiochemical syntheses, preclinical evaluation of new radiotracers in animal models, and implementation of unique new radiopharmaceuticals for human Positron Emission Tomography (PET) studies. His contributions to the field have been recognized by the Society of Nuclear Medicine (2009 Paul C. Aebersold Award for Outstanding Achievements in Basic Science Applied to Nuclear Medicine) and the Academy of Radiology Research (2012 Distinguished Investigator Award). For 25 years (1987-2012) he was the Director of PET Radiochemistry at the University of Michigan, during which time he designed, equipped, and brought into functional use (2005) a new Cyclotron and Radiochemistry Facility. More recently, he has provided consulting advice on new cyclotron and radiochemistry facilities being built in the United States, Mexico and South America.
Dr. Kilbourn maintains an active research program at the University of Michigan, currently funded by multiple research grants from the National Institutes of Health.
Expertise:
Facility design; equipment selection and evaluation; PET radiochemistry; preclinical radiotracer evaluation; facility operations including budgets, personnel, regulatory requirements; research grant writing.
Education:
B.S. (Biochemistry), University of Michigan-Dearborn, 1975
Ph.D. (Organic Chemistry), University of Illinois-Urbana, 1980
Postdoctoral (Radiochemistry), Brookhaven National Laboratory, 1980
Experience:
1980-1987 Dept. Radiology, Washington University-St. Louis
1987-present Dept. Radiology, University of Michigan
Publications (selected from >200):
1. Nabulsi NB, Smith DE and Kilbourn MR, [11C]Glycylsarcosine: synthesis and in vivo evaluation as a PET tracer of PepT2 transporter function in kidney of PepT2 null and wild type mice. Bioorg Med Chem 2005:13;2293-3001.
2. Ma B, Dennis JE, Caplan AI, Goldstein SA, Hankensen KA and Kilbourn, MR, A simple method for stem cell labeling with fluorine-18, Nucl Med Biol 2005:32;701-705.
3. Kilbourn MR, Hockley B, Lee L, Hou C, Goswami R, Ponde DE, Kung M-P, Kung HF. Pharmacokinetics of [18F]fluoroalkyl derivatives of dihydrotetrabenazine (DTBZ) in rat and monkey brain. Nuc Med Biol 2007:34;233-237.
4. Li X, Jung Y-W, Snyder S, Blair J, Sherman PS, Desmond KA, Frey KA and Kilbourn MR, 5-tert-butyl-2-(4’-[18F]fluoropropynylphenyl)-1,3-dithiane oxides: Potential new GABAA receptor radioligands. Nuc Med Biol 2008:35;549-559.
5. Scott PJH, Hockley BG, Kung HF, Manchanda R, Zhang W, Kilbourn MR, Studies into radiolytic decomposition of novel radiopharmaceuticals for Positron Emission Tomography, Appl Rad Isot 2009:67;88-94.
6. Shao X and Kilbourn MR, A simple modification of GE Tracerlab FX C Pro for preparation of [11C]carfentanil and [11C]raclopride. Appl Radiat Isot 2009:67;602-605.
7. Kilbourn MR, Hockley B, Lee Lihsueh, Sherman P, Quesada C, Frey KA and Koeppe RA, PET imaging of (2R,3R)-5-[18F]fluoroethoxybenzovesamicol ((-)-FEOBV) in rat and monkey brain: a radioligand for the vesicular acetylcholine transporter. Nucl Med Biol 2009:36;489-493.
8. Kilbourn MR, Butch ER, Desmond T, Sherman P, Harris P, Frey KA, Dopamine Depletion Increases In Vivo [11C]Dihydrotetrabenazine ([11C]DTBZ) Binding in Rat Striatum, Nucl Med Biol 2010:37;3-8.
9. Hefti FF, Kung HF, Kilbourn MR, Carpenter AP, Clark CM, Skovronsky DM, 18F-AV-133: a selective VMAT2-binding radiopharmacetical for PET imaging of dopaminergic neurons. PET Clinics 2010:5;75-82.
10. Kilbourn MR, Rat Pancreas Uptake of [11C]Dihydrotetrabenazine (DTBZ) Stereoisomers, Nucl Med Biol 2010:37;869-871.
11. Pichika R, Jewett D, Sherman PS, Traynor
JR, Husbands SM, Woods JH, Kilbourn MR, Synthesis and in vivo brain
distribution of carbon-11 labeled delta opioid receptor agonists, Nuc Med Biol
2010:37;989-99
12. Kilbourn MR and Domino EF, Increased In Vivo [11C]Raclopride Binding to Brain Dopamine Receptors in Amphetamine-Treated Rats, Eur J Pharmacol 2011:654;254-257.
Peter J. H. Scott, Ph.D.
Expertise:
Facility design; equipment selection and evaluation; PET radiochemistry; preclinical radiotracer evaluation; facility operations including budgets, personnel and regulatory requirements, regulatory submissions to US FDA, logistical and regulatory aspects of radiopharmaceutical distribution.
Education:
B.Sc. (Medicinal and Pharmaceutical Chemistry), Loughborough University, 2001
Ph.D. (Organic Chemistry), University of Durham, 2005
Postdoctoral (Organic Chemistry), State University of New York at Buffalo, 2005-2006
Postdoctoral (Radiochemistry), University of Michigan, 2006-2007
Experience:
2007-2009 Siemens Molecular Imaging and Biomarker Research, LA Tech Center, Los Angeles, CA
2009-present Division of Nuclear Medicine, Deptartment of
Radiology, University of Michigan, Ann Arbor, MI
Xia Shao, Ph.D.
Brian brings 11 years of radiochemistry research, radiopharmaceutical manufacturing, and management and governance experience to Synfast. Brian was educated at the University of Western Ontario, Canada where he studied the sciences and economics. He received a B.Sc. in Chemistry in 2001. Shortly after graduating Brian joined the PET research radiochemistry group at the University of Michigan under Dr. Michael Kilbourn. During his time at Michigan Brian has been directly involved in almost all facets of radiopharmaceutical research and product development, clinical translation, clinical trials, analytical quality control, quality improvement and regulatory management. He presently holds the position of Radiopharmaceutical Quality Assurance Manager at Michigan. He helped design and manage a customized systems-based regulatory compliance strategy for PET radiopharmaceutical manufacturing.
More recently Brian has expanded to other areas of management and governance. He is combining effective quality improvement and quality management with operational development and strategic planning models for resource-limited organizations in the non-profit sector. He currently sits on the Board of Directors of three non-profit organizations in health and human services, education and fund development and has served terms as President and Treasurer of the Board in addition to regular membership.
Selected Scientific Publications
1. Hockley, B.G., Scott, P.J.H. (2012). 18F-Fluoroazomycin arabinoside. Radiochemical Syntheses Volume I. P. J. H. Scott, M.R. Kilbourn, B.G. Hockley. Chichester, John Wiley & Sons, Ltd. (manuscript submitted)
2. Hockley, B.G., Scott, P.J.H. (2012). 18F-Sodium Fluoride. Radiochemical Syntheses Volume I. P. J. H. Scott, M.R. Kilbourn, B.G. Hockley. Chichester, John Wiley & Sons, Ltd. (manuscript submitted)
3. Hockley, B.G., Henderson, B.D., Shao, X., (2012). 11C-Choline.Chloride Radiochemical Syntheses Volume I. P. J. H. Scott, M.R. Kilbourn, B.G. Hockley. Chichester, John Wiley & Sons, Ltd. (manuscript submitted)
4. Shao, X., Hockley, B.G., Hoareau, R., Schnau, P.,Scott, P.J.H. (2011). “Fully automated preparation of [11C]choline and [18F]fluoromethylcholine using Tracerlab synthesis modules and facilitated quality control using HPLC.” Applied Radiation and Isotopes 69(2): 403-409.
5. Runkle, A.C., Shao, X., Tluczek, L.T., Henderson, B.D., Hockley, B.G., Scott, P.J.H. (2011). “Automated production of [11C]acetate and [11C]palmitate using a modified GE Tracerlab FXCPro.” Applied Radiation and Isotopes 69(4): 691-698
6. Shao, X., Hoareau, R., Runkle, A.C., Tluczek, L.J.M., Hockley, B.G., Henderson, B.D., Scott, P.J.H. (2011). “Highlighting the versatility of the Tracerlab synthesis modules. Part 2: fully automated production of [11C]-labeled radiopharmaceuticals using a Tracerlab FXC-Pro”. Journal of Labelled Compounds and Radiopharmaceuticals, 54(14), 819-838.
7. Shao, X., Hoareau, R., Hockley, B.H., Tluczek, L.J.M., Henderson, B.D., Padgett, H.C., Scott, P.J.H. (2011). “Highlighting the versatility of the Tracerlab synthesis modules. Part 1: fully automated production of [18F]-labeled radiopharmaceuticals using a Tracerlab FXFN”. Journal of Labelled Compounds and Radiopharmaceuticals, 54(6), 292-307.
8. Hockley, B.G. and Scott, P.J.H. (2010). "An automated method for preparation of [18F]sodium fluoride for injection, USP to address the technetium-99m isotope shortage." Applied Radiation and Isotopes 68(1): 117-119.
9. Hockley, B.G., Scott, P.J.H., Kilbourn, M.R. (2009). Solid Phase Radiochemistry. Linker Stratagies in Solid Phase Organic Synthesis. P. J. H. Scott. Chichester, John Wiley & Sons, Ltd.
10. Kilbourn, M.R., Hockley, B.G., Lee, L., Sherman, P., Quesada, Q., Frey, K., Koeppe, R.A. (2009). "PET imaging of (2R, 3R)-5-[18F]fluoroethoxybenzovesamicol in rat and monkey brain: a radioligand for the vesicular acetylcholine transporter." Nuclear Medicine and Biology 36(5): 489-493.
11. Scott, P.J.H., Hockley, B.G., Kung, H.F., Manchanda, R., Zhang, W., Kilbourn, M.R. (2009). "Studies into radiolytic decomposition of fluorine-18 labeled radiopharmaceuticals for positron emission tomography." Applied Radiation and Isotopes 67(1): 88-94.
12. Kilbourn, M.R., Hockley, B., Lee, L., Koeppe, R.A. (2008). "Successful [18F]FEOBV imaging of the VAChT in monkey brain." NeuroImage 41(Supplement 2): T93-T93.
13. Kilbourn, M.R., Hockley, B., et al. (2007). "Pharmacokinetics of [18F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain." Nuclear Medicine and Biology 34(3): 233-237.
